Treatment of opioid-dependent pregnant women: Clinical and research issues

Journal of Substance Abuse Treatment

Volumn 35, Issue 3, 2008, Pages 245-259

  Jones, Hendree E ^a   Martin, Peter R ^b   Heil, Sarah H ^c   Kaltenbach, Karol ^d   Selby, Peter ^e   Coyle, Mara G ^f   Stine, Susan M ^g   O'Grady, Kevin E ^h   Arria, Amelia M ^h   Fischer, Gabriele ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f BROWN UNIVERSITY   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Buprenorphine; Methadone; Opioid dependence; Pharmacologic treatment; Pregnancy; Substance abuse

Indexed keywords

AMANTADINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BUPRENORPHINE; CARBAMAZEPINE; CODEINE; DESIPRAMINE; DIPHENHYDRAMINE; DISULFIRAM; DOCUSATE SODIUM; EFAVIRENZ; FLUNITRAZEPAM; FLUOXETINE; FLUVOXAMINE; HYDROCODONE; HYDROXYZINE EMBONATE; INDINAVIR; KETOCONAZOLE; LOPERAMIDE; LOPINAVIR PLUS RITONAVIR; METHADONE; MORPHINE SULFATE; NALTREXONE; OMEPRAZOLE; OPIATE AGONIST; OXYCODONE; PARACETAMOL; RITONAVIR; SAQUINAVIR; TUMS; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ALCOHOL ABUSE; ARTICLE; BREAST FEEDING; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONSTIPATION; DELIVERY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INDIGESTION; LABOR; LOW DRUG DOSE; MEDICAL ASSESSMENT; MENTAL DISEASE; METHADONE TREATMENT; MOTIVATION; OPIATE ADDICTION; OPTIMAL DRUG DOSE; PAIN; PATIENT EDUCATION; PRACTICE GUIDELINE; PREGNANT WOMAN; PRENATAL CARE; PRESCRIPTION; PRIORITY JOURNAL; PUERPERIUM; RESTLESSNESS; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME;

ANALGESICS, OPIOID; BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; DECISION MAKING; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; OPIOID-RELATED DISORDERS; PAIN; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 49249099427     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2007.10.007     Document Type: Article

References (130)

1. Abdel-Latif M.E., Pinner J., Clews S., Cooke F., Lui K., and Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 117 (2006) e1163-e1169
2. Alford D.P., Compton P., and Samet J.H. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of Internal Medicine 144 (2006) 127-134
3. Amass L., Bickel W.K., Crean J.P., Blake J., and Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opiate-dependent humans. Psychopharmacology 136 (1998) 217-225
4. Amass L., Bickel W.K., Higgins S.T., and Badger G.J. Alternate-day dosing during buprenorphine treatment of opiate dependence. Life Sciences 54 (1994) 1215-1228
5. Amass L., Kamien J.B., and Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence 58 (2000) 143-152
6. Amass L., Kamien J.B., and Mikulich S.K. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug and Alcohol Dependence 61 (2001) 173-181
7. Auriacombe M., and Loustauneau A. Medical treatment of the pregnant heroin addict--Review of the literature. In: Pregnancy and drug misuse update 2000. Proceedings: Seminar organized by the Co-operation Group to Combat Drug Abuse and Illicit Trafficking in Drugs (Pompidou Group), Strasbourg, France, 29-30 May 2000. Drugs and Addiction. Council of Europe (2000) 39-74
8. Bertschy G., and Baumann P. Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: A case report. Biological Psychiatry 38 (1995) 404-406
9. Bertschy G., Eap C.B., Powell K., and Baumann P. Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects. Therapeutic Drug Monitoring 18 (1996) 570-572
10. Bickel W.K., Amass L., Crean J.P., and Badger G.J. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology 146 (1999) 111-118
11. Blinick G., Wallach R.C., and Jerez E. Pregnancy in narcotics addicts treated by medical withdrawal: The methadone detoxification program. American Journal of Obstetrics and Gynecology 105 (1969) 997-1003
12. Bonari L., Pinto N., Ahn E., Einarson A., Steiner M., and Koren G. Perinatal risks of untreated depression during pregnancy. Canadian Journal of Psychiatry 49 (2004) 726-735
13. Brunton P.J., Meddle S.L., Ma S., Ochedalski T., Douglas A.J., and Russell J.A. Endogenous opioids and attenuated hypothalamic-pituitary-adrenal axis responses to immune challenge in pregnant rats. Journal of Neuroscience 25 (2005) 5117-5126
14. Burns K., Melamed J., Burns W., Chasnoff I., and Hatcher R. Chemical dependence and clinical depression in pregnancy. Journal of Clinical Psychology 41 (1985) 851-854
15. Carroll K.M., Easton C.J., Nich C., et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. Journal of Consulting and Clinical Psychology 74 (2006) 955-966
16. Center for Substance Abuse Treatment. State methadone treatment guidelines. (Treatment improvement protocol series 1) (1993), U.S. Department of Health and Human Services, Rockville, MD
17. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. (Treatment improvement protocol series 40) (2004), U.S. Department of Health and Human Services, Rockville, MD
18. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. (Treatment improvement protocol series 43) (2005), U.S. Department of Health and Human Services, Rockville, MD
19. Chambers C.D., Hernandez-Diaz S., Van Marter, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine 354 (2006) 579-587
20. Chiang C.N., and Hawks R.L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence 70 (2003) S39-S47
21. Cohen R., Mrtek M.B., and Mrtek R.G. Comparison of maternal absenteeism and infant illness rates among breast-feeding and formula-feeding women in two corporations. American Journal of Health Promotion 10 (1995) 148-153
22. Cohen L.S., Nonacs R., Viguera A.C., and Reminick A. Diagnosis and treatment of depression during pregnancy. CNS Spectrums 9 (2004) 209-216
23. Comfort M., Zanis D.A., Whiteley M.J., Kelly-Tyler A., and Kaltenbach K.A. Assessing the needs of substance abusing women. Psychometric data on the psychosocial history. Journal of Substance Abuse Treatment 17 (1999) 79-83
24. Connaughton J.F., Resser D., Schut J., and Finnegan L.P. Perinatal addiction: Outcome and management. American Journal of Obstetrics and Gynecology 129 (1977) 679-686
25. Cowan A. Update of the general pharmacology of buprenorphine. In: Lewis J., and Cowan A. (Eds). Buprenorphine: Combating drug abuse with a unique opioid (1995), Wiley, New York 31-47
26. DeMaria P.A., and Serota R.D. Therapeutic use of the methadone fluvoxamine drug interaction. Journal of Addictive Diseases 18 (1999) 5-12
27. DePetrillo P.B., and Rice J.M. Methadone dosing and pregnancy: Impact on program compliance. International Journal of Addiction 30 (1995) 207-217
28. Douglas A.J., Meddle S.L., Toschi N., Bosch O.J., and Neumann I.D. Reduced activity of the noradrenergic system in the paraventricular nucleus at the end of pregnancy: Implications for stress hyporesponsiveness. Journal of Neuroendocrinology 17 (2005) 40-48
29. Drozdick III J., Berghella V., Hill M., and Kaltenbach K. Methadone trough levels in pregnancy. American Journal of Obstetrics and Gynecology 187 (2002) 1184-1188
30. Dunlop A., Panjari M., O'Sullivan H., et al. Clinical guidelines for the use of buprenorphine during pregnancy (2003), Turning Point Alcohol and Drug Centre, Fitzroy
31. Eap C.B., Buclin T., and Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clinical Pharmacokinetics 41 (2002) 1153-1193
32. Eder H., Fischer G., Gombas W., Jagsch R., Stuhlinger G., and Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. European Addiction Research 4 Suppl 1 (1998) 3-7
33. Einarson A., Selby P., and Koren G. Discontinuing antidepressants and benzodiazepines upon becoming pregnant. Beware of the risks of abrupt discontinuation. Canadian Family Physician 47 (2001) 489-490
34. Eissenberg T., Greenwald M.K., Johnson R.E., Liebson I.A., Bigelow G.E., and Stitzer M.L. Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics 276 (1996) 449-459
35. Ernst E., Bartu A., Popescu A., Ileutt K.F., Hansson R., and Plumley N. Methadone-related deaths in Western Australia 1993-1999. Australian and New Zealand Journal of Public Health 26 (2002) 364-370
36. Festinger D.S., Lamb R.J., Kirby K.C., and Marlowe D.B. The accelerated intake: A method for increasing initial attendance to outpatient cocaine treatment. Journal of Applied Behavior Analysis 29 (1996) 387-389
37. Festinger D.S., Lamb R.J., Kountz M.R., Kirby K.C., and Marlowe D. Pretreatment dropout as a function of treatment delay and client variables. Addictive Behaviors 20 (1995) 111-115
38. Festinger D.S., Lamb R.J., Marlowe D.B., and Kirby K.C. From telephone to office: Intake attendance as a function of appointment delay. Addictive Behaviors 27 (2002) 131-137
39. Finnegan L.P. Perinatal substance abuse: Comments and perspectives. Seminars in Perinatology 15 (1991) 331-339
40. Fischer G., Etzersdorfer P., Eder H., et al. Buprenorphine maintenance in pregnant opiate addicts. European Addiction Research 4 Suppl 1 (1998) 32-36
41. Fischer G., Johnson R.E., Eder H., et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95 (2000) 239-244
42. Fischer G., Ortner R., Rohrmeister K., et al. Methadone versus buprenorphine in pregnant addicts: A double-blind, double-dummy comparison study. Addiction 101 (2006) 275-281
43. Fitzsimons H.E., Tuten M., Vaidya V., and Jones H.E. Mood disorders affect drug treatment success of drug-dependent pregnant women. Journal of Substance Abuse Treatment 32 (2007) 19-25
44. Fornataro K. Methadone and anti-HIV drugs. The Body Positive 12 (1999) 13
45. Friedland G., Andrews L., Schreibman T., et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19 (2005) 1635-1641
46. Gazaway P.M., Bigelow G.E., and Brooner R.K. The influence of pregnancy upon trough plasma levels of methadone and its opioid effects. NIDA research monograph 132 (1993) 112
47. George T.P., Chawarski M.C., Pakes J., Carroll K.M., Kosten T.R., and Schottenfeld R.S. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biological Psychiatry 47 (2000) 1080-1086
48. Gerstein D.R. The effectiveness of drug treatment. Research Publications-Association for Research in Nervous and Mental Disease 70 (1992) 253-282
49. Greenwald M., Johanson C.E., Bueller J., et al. Buprenorphine duration of action: Mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biological Psychiatry 61 (2007) 101-110
50. Greenwald M.K., Schuh K.J., Hopper J.A., Schuster C.R., and Johanson C.E. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology (Berl) 160 (2002) 344-352
51. Gunderson E.W., and Stimmel B. Treatment of pain in drug-addicted persons. In: Galanter M., and Kleber H. (Eds). Textbook of Substance Abuse Treatment. 3rd ed. (2004), American Psychiatric Pub Inc, Washington, DC 563-574
52. Haller D.L., Knisley J.S., Dawson K.S., et al. Perinatal substance abusers. Psychological and social characteristics. Journal of Nervous Mental Diseases 181 (1993) 509-513
53. Handelsman L., Stein J.A., and Grella C.E. Contrasting predictors of readiness for substance abuse treatment in adults and adolescents: A latent variable analysis of DATOS and DATOS-A participants. Drug and Alcohol Dependence 80 (2005) 63-81
54. Ibrahim R.B., Wilson J.G., Thorsby M.E., and Edwards D.J. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sciences 66 (2000) 1293-1298
55. Iribarne C., Berthou F., Carlhant D., et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metabolism and Disposition 26 (1998) 257-260
56. Iribarne C., Picart D., Dréano Y., and Bail J.-P. Involvement of cytochrome P4503A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sciences 60 (1997) 1953-1964
57. Iribarne C., Picart D., Dreano Y., and Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundamental and Clinical Pharmacology 12 (1998) 194-199
58. Jansson L.M., Dipietro J., and Elko A. Fetal response to maternal methadone administration. American Journal of Obstetrics and Gynecology 193 3 Pt 1 (2005) 611-617
59. Jansson L.M., Dipietro J.A., Elko A., and Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. Journal of Maternal, Fetal and Neonatal Medicine 20 (2007) 677-685
60. Johnson R.E., Jones H.E., and Fisher G. Use of buprenorphine in pregnancy: Patient management and effects on the neonate. Drug and Alcohol Dependence 70 (2003) S87-S101
61. Johnson R.E., Jasinski D.R., and Milio L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug and Alcohol Dependence 78 (2005) 33-38
62. Johnson R.E., Jones H.E., Jasinski D.R., Svikis D.S., Haug N.A., Jansson L.M., et al. Buprenorphine treatment of pregnant opioid--dependent women: Maternal and neonatal. Drug and Alcohol Dependence 63 (2001) 97-103
63. Jones H.E. Drug addiction during pregnancy: Advances in maternal treatment and understanding child outcomes. Current Directions for Psychological Science 15 (2006) 126-130
64. Jones H.E., Johnson R.E., and Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. American Journal on Addictions 15 (2006) 258-259
65. Jones, H. E., Johnson, R. E., O'Grady, K. E., Jasinski, D. R., & Milio, L. (in press). Dosing adjustments in post-partum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine.
66. Jones H.E., Jones H.E., Johnson R.E., Jasinski D.R., et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence 79 (2005) 1-10
67. Jones, H. E., O'Grady, K. E., Schlundt, D., & Tuten, M. (Submitted a). Methadone maintenance vs. methadone taper: Maternal and neonatal outcomes.
68. Jones H.E., Suess P., Jasinski D.R., and Johnson R.E. Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: An open-label exploratory study. American Journal of Addiction 15 (2006) 61-70
69. Kaltenbach K., Berghella V., and Finnegan L. Opioid dependence during pregnancy: Effects and management. Obstetrics and Gynecology Clinics of North America 25 (1998) 139-151
70. Kandall S.R., Albin S., Gartner L.M., Lee K.S., Eidelman A., and Lowinson J. The narcotic-dependent mother: Fetal and neonatal consequences. Early Human Development 1 (1977) 159-169
71. Kilicarslan T., and Sellers E.M. Lack of interaction of buprenorphine with flunitrazepam metabolism. American Journal of Psychiatry 157 (2000) 1164-1166
72. Kintz P. A new series of 13 buprenorphine-related deaths. Clinical Biochemistry 35 (2002) 513-516
73. Kintz P. Buprenorphine-related deaths. In: Kintz P., and Marquet P. (Eds). Buprenorphine therapy of opiate addiction (2002), Totowa, Humana Press 109-118
74. Kissin W.B., Svikis D.S., Moylan P., Haug N.A., and Stitzer M.L. Identifying pregnant women at risk for early attrition from substance abuse treatment. Journal of Substance Abuse Treatment 27 (2004) 31-38
75. Kosten T.R., Krystal J.H., Charney D.S., Price L.H., Morgan C.H., and Kleber H.D. Opiate antagonist challenges in buprenorphine-maintained patients. Drug and Alcohol Dependence 25 (1990) 73-78
76. Kosten T.R., Morgan C.M., Falcione J., and Schottenfeld R.S. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Archives of General Psychiatry 49 (1992) 894-898
77. Kosten T.R., Oliveto A., Sevarino K.A., Gonsai K., and Feingold A. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug Alcohol Dependence 66 (2002) 173-180
78. Kreek M. Methadone disposition during the perinatal periods in humans. Pharmacology, Biochemistry and Behavior 11 (1979) 7-13
79. Kreek M. Drug interactions with methadone in humans. NIDA research monograph 68 (1986) 193-225
80. Kreek M., Schecter A., and Gutjahr C. Analyses of methadone and other drugs in maternal and neonatal body fluids: Use in evaluation of symptoms in a neonate of mother maintained on methadone. American Journal of Drug Alcohol Abuse 1 (1974) 409-419
81. Kulin N.A., Pastuszak A., and Koren G. Are the new SSRIs safe for pregnant women?. Canadian Family Physician 44 (1998) 2081-2083
82. Lejeune C., Simmat-Durand L., Gourarier L., et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Dependence 82 (2006) 250-257
83. Lintzeris N., Ritter A., Dunlop A., and Muhleisen P. Training primary health care professionals to provide buprenorphine and LAAM treatment. Substance Abuse 23 (2002) 245-254
84. Lussier J.P., Heil S.H., Mongeon J.A., Badger G.J., and Higgins S.T. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 101 (2006) 192-203
85. Malpas T.J., and Darlow B.A. Neonatal abstinence syndrome following abrupt cessation of breastfeeding. New Zealand Medical Journal 112 (1999) 12-13
86. McCance-Katz E.F., Gourevitch M.N., Arnsten J., Sarlo J., Rainey P., and Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. American Journal on Addictions 11 (2002) 271-278
87. McCance-Katz E.F., Moody D.E., Morse G.D., et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clinical Infectious Diseases 43 Suppl 4 (2006) S224-S234
88. McCance-Katz E.F., Moody D.E., Morse G.D., et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug and Alcohol Dependence (2007) (electronic publication ahead of print)
89. McCance-Katz E.F., Rainey P.M., Friedland G., and Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical Infectious Diseases 37 (2003) 476-482
90. McCance-Katz E.F., Rainey P.M., Friedland G., Kosten T.R., and Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. American Journal on Addictions 10 (2001) 296-307
91. McCance-Katz E.F., Rainey P.M., Jatlow P., and Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). Journal of Acquired Immune Deficency Syndromes and Human Retrovirology 18 (1998) 435-443
92. McLellan A.T., Kushner H., Metzger D., et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 9 (1992) 199-213
93. Meador K.J., Baker G.A., Finnell R.H., et al. In utero antiepileptic drug exposure: Fetal death and malformations. Neurology 67 (2006) 407-412
94. Meyer M., Paranya G., Kristensen E., and Plante D. Buprenorphine impairs intrapartum patient controlled epidural analgesia (PCEA) efficacy. Poster presentation presented at the annual meeting of the Society of Obstetric Anesthesia and Perinatology, Alberta, Canada (2007)
95. Meyer M., Wagner K., Benvenuto A., Howard D., and Plante D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstetrics and Gynecology 110 (2007) 261-266
96. Meyers R.J., and Smith J.E. Clinical guide to alcohol treatment. The community reinforcement approach (1995), Guilford Press, New York
97. Nanovskaya T.N., Deshmukh S.V., Nekhayeva I.A., Zharikova O.L., Hankins G.D., and Ahmed M.S. Methadone metabolism by human placenta. Biochemical Pharmacology 68 (2004) 583-591
98. National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Journal of the American Medical Association 280 (1998) 1936-1943
99. Oliveto A., Kosten T.R., Schottenfeld R., Falcioni J., and Ziedonis D. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. Journal of Substance Abuse Treatment 12 (1995) 423-428
100. Paetzold W., Eronat V., Seifert J., Holze I., Emrich H.M., and Schneider U. Detoxification of poly-substance abusers with buprenorphine. Effects on affect, anxiety, and withdrawal symptoms. Nervenarzt 71 (2000) 722-729
101. Peachey J.E., and Lei H. Assessment of opioid dependence with naloxone. British Journal of Addiction 83 (1988) 193-201
102. Petry N.M., Bickel W.K., and Badger G.J. A comparison of four buprenorphine dosing regimens using open-dosing procedures: Is twice-weekly dosing possible?. Addiction 95 (2000) 1069-1077
103. Petry N.M., Bickel W.K., and Badger G.J. Examining the limits of the buprenorphine interdosing interval: Daily, every-third-day and every-fifth-day dosing regimens. Addiction 96 (2001) 823-834
104. Pond S., Kreek M., Tong T., et al. Changes in methadone pharmacokinetics during pregnancy. Journal of Pharmacology and Experimental Therapeutics 234 (1985) 1-6
105. Ramirez-Cacho W.A., Flores S., Schrader R.M., McKay J., and Rayburn W.F. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. Journal for the Society of Gynecological Investigation 13 (2006) 108-111
106. Rawson R.A., Huber A., McCann M., et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of General Psychiatry 59 (2002) 817-824
107. Records K., and Rice M.J. A comparative study of postpartum depression in abused and nonabused women. Archives of Psychiatric Nursing 19 (2005) 281-290
108. Regan D., Leifer B., Matteucci T., and Finnegan L. Depression in pregnant drug-dependent women. NIDA research monograph 41 (1982) 466-472
109. Rementeria J.L., and Nunag N.N. Narcotic withdrawal in pregnancy: Stillbirth incidence with a case report. American Journal of Obstetrics and Gynecology 116 (1973) 1152-1156
110. Reynaud M., Petit G., Potard D., and Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93 (1998) 1385-1392
111. Schlatter J., Madras J.L., Saulnier J.L., and Poujade F. Drug interactions with methadone. Presse Medicine 28 (1999) 1381-1384
112. Singh R.A., Mattoo S.K., Malhotra A., and Varma V.K. Cases of buprenorphine abuse in India. Acta Psychiatry Scandinavia 86 (1992) 46-48
113. Srivastava A., and Kahan M. Methadone induction doses: Are our current practices safe?. Journal of Addictive Diseases 25 (2006) 5-13
114. Stark M.J., Campbell B.K., and Brinkerhoff C.V. "Hello, may we help you?" A study of attrition prevention at the time of the first phone contact with substance-abusing clients. American Journal of Drug and Alcohol Abuse 16 (1990) 67-76
115. Stasiewicz P.R., and Stalker R. A comparison of three "interventions" on pretreatment dropout rates in an outpatient substance abuse clinic. Addictive Behaviors 24 (1999) 579-582
116. Stevens R.C., Rapaport S., Maroldo-Connelly L., Patterson J.B., and Bertz R. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. Journal of Acquired Immune Deficiency Syndrome 33 (2003) 650-651
117. Strain E.C., Preston K.L., Liebson I.A., and Bigelow G.E. Precipitated withdrawal by pentazocine in methadone-maintained volunteers. Journal of Pharmacology and Experimental Therapeutics 267 (1993) 624-634
118. Tong T.G., Benowitz N.L., and Kreek M.J. Methadone-disulfiram interaction during methadone maintenance. Journal of Clinical Pharmacology 20 (1980) 506-513
119. U.S. Department of Health and Human Services. HHS blueprint for action on breastfeeding (2000), U.S. Government Printing Office, Washington, DC
120. U.S. Department of Health and Human Services. Healthy people 2010. Understanding and improving health. Chapter 16. 2nd ed. (2000), U.S. Government Printing Office, Washington, DC
121. Virden S.F. The relationship between infant feeding method and maternal role adjustment. Journal of Nurse-Midwifery 33 (1988) 31-35
122. Wesson D.R., and Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 35 (2003) 253-259
123. White J.M., and Irvine R.J. Mechanisms of fatal opioid overdose. Addiction 94 (1999) 961-972
124. Widstrom A.M., Wahlberg V., Matthiesen A.S., et al. Short-term effects of early suckling and touch of the nipple on maternal behaviour. Early Human Development 21 (1990) 153-163
125. Wilson G.S., Desmond M.M., and Wait R.B. Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: Health, developmental, and social implications. Journal of Pediatrics 98 (1981) 716-722
126. Wittmann B.K., and Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: Ultrasound evaluation. International Journal of Addiction 26 (1991) 213-218
127. Wunsch M.J., Stanard V., and Schnoll S.H. Treatment of pain in pregnancy. Clinical Journal of Pain 19 (2003) 148-155
128. Zharikova O.L., Deshmukh S.V., Kumar M., et al. The effect of opiates on the activity of human placental aromatase/CYP19. Biochemical Pharmacology 73 (2007) 279-286
129. Zharikova O.L., Deshmukh S.V., Nanovskaya T.N., Hankins G.D., and Ahmed M.S. The effect of methadone and buprenorphine on human placental aromatase. Biochemical Pharmacology 71 (2006) 1255-1264
130. Zuspan F.P., Gumpel J.A., Mejia-Zelaya A., Madden J., and Davis R. Fetal stress from methadone withdrawal. American Journal of Obstetrics and Gynecology 122 (1975) 43